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Pancreatic ductal adenocarcinoma, also known as pancreatic cancer, is one of the most 53 aggressive diseases in the world. The five year survival rate is below 7% and median survival 54 is approximately 6 months. While relatively low in prevalence, pancreatic cancer is the fourth 55 leading cause of cancer-related death [1] [2] [3] . More seriously, the prognosis of pancreatic 56 cancer patients remains unchanged, in spite of significant improvements in overall survival 57 rates of other cancers [4] . Effective blockade of pancreatic cancers is urgently required.
58
One of the major features of pancreatic cancer is the high resistance to conventional 59 cancer therapies including chemotherapy and radiation therapy. Another serious feature of 60 pancreatic cancers is its early distant metastasis and locally abnormal progression, which 61 contributes to the relative rarity of surgery [5, 6] . The more fundamental reason for the 62 extremely poor prognosis may be that only few patients undergo surgical operations on lack 63 of diagnosis [7] . Thus, early diagnosis is of vital significance.
64
To date, the diagnosis of pancreatic cancer after the onset of symptoms includes the 10]. The search continues for a truly effective diagnostic marker for pancreatic cancer 76 patients.
77
Dual specificity phosphatases (DUSPs) are a heterogeneous group of protein 78 phosphatases that regulate mitogen-activated protein kinases (MAPKs). DUSPs have been 79 implicated as critical modulators of intracellular signaling pathways involved in various 80 diseases including malignant cancers [11, 12] . So far, 25 DUSP genes have been listed in 81 Human Genome Organization databases. These can be subdivided into three groups by 82 subcellular expression. Class I DUSPs including DUSP1, 2, 4, and 5 are localized to the 83 nucleus, while Class II DUSPs including DUSP6, 7, and 16 are found in the cytoplasm. Class
84
III DUSPs including DUSP8, 9, and 10 can be localized in the nucleus or the cytoplasm 15]. Interestingly, we previously reported that DUSP28 can be detected in cultured medium 86 of Capan-1 human metastatic pancreatic cancer cells [16] . Although we have proposed the 87 first expression type of DUSPs, its underlying understanding remains poor.
88
In the present study, we provide the first evidence that metastatic human pancreatic 89 cancers produce the functionally secreted DUSP28 protein, which is critical in metastatic 90 pancreatic cancer malignancy via autocrine signaling pathways. Our results provide a 91 rationale for secreted DUSP28 as a therapeutic target and an effective biomarker for 92 metastatic pancreatic cancer patients. We have previously reported that Capan-1 human metastatic pancreatic cancer cells 105 specifically secrete DUSP28 (sDUSP28) to the cultured medium compared to six other 106 pancreatic cancer cell types [16] . To confirm the release of DUSP28 in metastatic pancreatic 107 cancer cells, we additionally used CFPAC-1 human metastatic pancreatic cancer cells and 108 SNU-213 cells, which weakly express DUSP28, for sandwich-ELISA and immune-109 precipitation [17, 18] . DUSP28 were clearly detected in cultured supernatants of Capan-1 and fig. 1A , B). Next, we prepared 111 recombinant DUSP28 (rDUSP28) to evaluate the effects of the DUSP28 in features of human 112 metastatic pancreatic cancer. As shown in figure 1A , rDUSP28 showed a significant and denatured DUSP28 (25 µg/mL) had no effect on migration of Capan-1 and CFPAC-1 cell.
110
CFPAC-1 cells, but not SNU-213 cells (Supplementary
117
Exogenously treated with DUSP28 also significantly induced the invasion of Capan-1 and 118 CFPAC-1 cells in a dose-dependent manner; in contrast, denatured DUSP28 had no effect on 119 invasion of Capan-1 and CFPAC-1 cell (Fig. 1B) . In addition, the viability of Capan-1 and 120 CFPAC-1 cells was significantly increased in a dose-dependent manner by sDUSP28 121 treatment; however, denatured rDUSP28 had no effect on viability of Capan-1 and CFPAC-1 122 cell (Fig. 1C) . To understand the mechanism by which sDUSP28 aggravated the malignancy 123 of human metastatic pancreatic cancer cells, we examined the signal transduction pathways 124 using phospho-MAPK array. Exogenous rDUSP28 treatment induced a significant increase in 125 phosphorylation of various MAPK molecules including AKT2 (1.45 fold), CREB (1.25 fold), 126 ERK1 (1.56 fold), ERK2 (1.34 fold), heat shock protein (HSP)27 (1.14 fold), and target of 127 rapamycin (TOR) (1.58 fold) in Capan-1 cells compared to control cells (Fig. 1D) . To further 128 analyze the detailed mechanism of DUSP28 treatment in Capan-1 cells, the levels of 129 phosphorylated CREB, AKT, and ERK1/2 were examined with different lengths of time in 130 rDUSP28 treatment. Exogenous DUSP28 treatment increased phosphorylation of CREB,
131
AKT, and ERK1/2 in a time-dependent manner (Fig. 1E) (Fig. 2E, F) . Inhibition of ITGα1 expression was also remarkably decreased the 169 phosphorylation of CREB, AKT, and ERK1/2 activated by exogenous rDUSP28 treatment 170 compared to those in scrambled si-RNA transfected cells, respectively (Fig. 2G) . According 171 to the GSE57495 data-set, low ITGα1 expression significantly improves median survival by 172 391 days compared to that of a high level of ITGα1 (Fig. 2H) We next tested whether DUSP28 can induce pro-angiogenic effects in HUVECs due to its Treatment with rDUSP28 also significantly increased on the viability of HUVECs as the 197 treated dosages increased (15 µg/mL: 1.12-fold; 25 µg/mL: 1.19-fold) (Fig. 3B) . Since Migration assays were performed using a 24-well Trans-well apparatus (Corning, Corning,
351
NY, USA), as described previously [25] . Cells were applied to the upper chamber containing 352 serum-free RPMI and the cells that migrated to the underside of the filter in 6 h were stained.
353
The eluted dye was measured at 560 nm in an ELISA reader (Bio-Rad). (rDUSP28) or denatured rDUSP28 for 6 h. Migration was evaluated using the Transwell 575 migration assay (n = 3; Tukey's post-hoc test was applied to detect significant group effects 576 as determined by analysis of variance, P < 0.0001; asterisks indicate a significant difference 577 vs. 0% inhibition, **P < 0.01, **P < 0.01, n.s., non-significant). B. Capan-1 and CFPAC-1 578 cells were incubated with various concentrations of rDUSP28 or denatured rDUSP28 for 24 h.
579
Invasion was evaluated using the Transwell invasion assay (n = 3; Tukey's post-hoc test was 580 applied to detect significant group effects as determined by analysis of variance, P < 0.0001; 581 asterisks indicate a significant difference vs. 0% inhibition, **P < 0.01, **P < 0.01, n.s., non-582 significant). C. Capan-1 and CFPAC-1 cells were incubated with various concentrations of 583 rDUSP28 or denatured rDUSP28 for 72 h under serum-free cultured condition. Viability was 584 measured by the WST-1 assay (n = 3; Tukey's post hoc test was applied to significant group 585 effects in ANOVA, p < 0.0001; asterisks indicate a significant difference compared with 0% 586 inhibition, *P < 0.05, **P < 0.01, n.s., non-significant). D. Capan-1 cells were incubated with 587 rDUSP28 (25 µg/mL) for 24 h. Phospho MAPK array was used to determine differences in Western blot analysis using antibodies specific for phospho-CREB, total CREB, phospho-594 AKT, total AKT, phospho-ERK1/2, total ERK1, and GAPDH. Relative pixel intensities for p-595 CREB, p-AKT, p-ERK1/2 were measured using pCREB/CREB, pAKT/AKT, and 596 pERK1/2/ERK1 by densitometry analysis using ImageJ analysis software. F. Protein-protein 597 interaction (PPI) networks of AKT2, CREB, ERK1, ERK2, HSP27, and TOR in pancreatic 598 cancer were constructed using The Human Protein Reference Database. Transwell-assay for an additional 6 for migration or 24 h for invasion, respectively (n = 3;
610
Tukey's post-hoc test was used to detect significant difference in ANOVA, p < 0.0001; 611 asterisks indicate a significant difference compared with 0% inhibition, ***P < 0.001). D.
612
Capan-1 cells were transfected with scrambled or ITGα1-siRNAs for 72h. Viability was 613 measured by the WST-1 assay (P value was calculated using the Student's t-test). E. Capan-1 614 and CFPAC-1 cells were transfected with scrambled or ITGα1-siRNAs for 48h. Exogenous 615 rDUSP28 (25 µg/mL) was pretreated for 1h. Migrated cells were evaluated using the
616
Transwell-assay for a 6h (n = 3; Tukey's post-hoc test was used to detect significant 617 difference in ANOVA, p < 0.0001; asterisks indicate a significant difference compared with 618 0% inhibition, ***P < 0.001). F. Capan-1 and CFPAC-1 cells were transfected with 619 scrambled or ITGα1-siRNAs for 48h. Exogenous rDUSP28 (25 µg/mL) was pretreated for 1h.
620
Invasive cells were evaluated using the Transwell-assay for a 24h (n = 3; Tukey's post-hoc 621 test was used to detect significant difference in ANOVA, p < 0.0001; asterisks indicate a 622 significant difference compared with 0% inhibition, ***P < 0.001). G. Capan-1 cells were 623 transfected with scrambled or ITGα1-siRNAs for 48h. Exogenous rDUSP28 (25 µg/mL) was 624 treated for 6h and the cell lysates were subjected to Western blot using antibodies specific for 625 phospho-CREB, total CREB, phospho-AKT, total AKT, phospho-ERK1/2, total ERK1, and 626 GAPDH. H. Kaplan-Meier plot of the median survival for pancreatic cancer patients included 627 dependent on differential expressions of ITGα1 (P value was calculated using Log-rank (Mantel-Cox) Test, respectively). 
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0% inhibition, *P < 0.05, **P < 0.01, ***P < 0.001, n.s., non-significant, scale bar = 50 µm). experiments, **P < 0.01, ***P < 0.001, n.s., non-significant). D. HUVECs were incubated at 643 25 µg/mL of rDUSP28 in a time-dependent manner, and cell lysates were subjected to 644 Western blot using antibodies for p-FAK and p-ERK1/2. GAPDH was used as loading control.
645
Relative pixel intensities for p-FAK and p-ERK1/2 were measured using pFAK/FAK and 646 pERK1/2/ERK1 by densitometry analysis using ImageJ analysis software. E. Effects of 647 rDUSP28 (30 mg/kg) injection in Capan-1 xenograft models (Mock group: n = 6 and 648 sDUSP28 injection group: n = 6) were measured for 22 days using the formula: V = 0. Capan-1 and SNU-213 xenograft models (normal, non-tumor bearing nude mice). C.
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Concentrations of sDUSP28 were analyzed by a sandwich ELISA using whole bloods from si-ITGα1 
C
Capan-1 (n=4) 
